Nanoscope Therapeutics Announces Participation in Upcoming Ophthalmology Conferences
Nanoscope Therapeutics will participate in the Eyecelerator 2026 and American Academy of Ophthalmology (AAO) Annual Meeting, where it plans to present updates on its optogenetics gene therapy MOGENRY®. The company's Chief Medical Officer, Dr. Sam Barone, is scheduled to join a panel discussing emerging innovations in retinal therapies. Additionally, Nanoscope will showcase progress toward global approval of MCO-010 for inherited retinal dystrophies and present four-year data from the RESTORE trial on vision improvement in patients with retinitis pigmentosa. The AAO 2026 meeting is a major event where ophthalmologists gather to discuss advancements. Nanoscope will also share findings related to dry AMD treatment using sonpiretigene isteparvovec, based on the first direct-to-Phase 2 randomized controlled trial. These presentations aim to highlight the durability and potential of optogenetic therapies in treating retinal degeneration. The company's leadership team is expected to engage with retina specialists, investors, and partners during these events.
Topics: Biotechnology Clinical Trials Gene Therapy Ophthalmology